Coverage
Filings
| Filing | Date |
|---|---|
| Transaction in Own Shares | 3 Oct 2025 |
| Transaction in Own Shares | 2 Oct 2025 |
| Total Voting Rights | 1 Oct 2025 |
| Transaction in Own Shares | 1 Oct 2025 |
| GSK - third tranche of share buyback programme | 30 Sept 2025 |
| GSK appoints CEO designate | 29 Sept 2025 |
| Director/PDMR Shareholding | 22 Sept 2025 |
| Transaction in Own Shares | 19 Sept 2025 |
| Transaction in Own Shares |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 18 Sept 2025 |
| Transaction in Own Shares | 17 Sept 2025 |
| GSK US Investment Announcement | 17 Sept 2025 |
| Transaction in Own Shares | 16 Sept 2025 |